NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Breast Cancer



ACIS assessment of HER-2/neu expression fast, accurate, and cost-effective



March 9th, 2006

Assessment of HER-2/neu expression in breast tumors using the ACIS system (ChromaVision Medical Systems, Inc., San Juan Capistrano, CA) is fast, accurate, and cost-effective.

"Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) are both commonly used assays for evaluation of HER-2/neu status in breast cancer," pathologists in the United States explained. "However, there is still no consensus on which method is most predictive of patient response to Herceptin."

"Recently, the automated cellular imaging system (ACIS) has been shown to improve the accuracy and reproducibility in scoring IHC," noted O.W. Tawfik and...


Source: Women's Health Weekly (2006-03-09)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login